Company intelligence / Profile preview
Palisade Bio
- Ownership
- Public · PALI
- Employees
- ~8
- Development stage
- Phase 2
Overview
Palisade Bio's lead candidate, PALI-2108, a prodrug PDE4 inhibitor, has completed single ascending dose (SAD), multiple ascending dose (MAD), food effect studies and first UC patient dosing in Phase 1a/b. Topline data are expected in the first half of 2025. The company also has a program targeting fibrostenotic Crohn’s disease at the discovery/early clinical stage. Both programs aim to address unmet needs in immune-mediated inflammatory and fibrotic diseases by improving efficacy and safety over existing therapies through precision targeting.
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecules (prodrug PDE4 inhibitors)
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $202.2M
- Total revenue
- $0
- Enterprise value
- $77M
Beyond the preview
Go deeper on Palisade Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Palisade Bio.